Desmopressin for nocturnal enuresis in nephrogenic diabetes insipidus.

Abstract

We have investigated two unrelated families, in which two children had inherited primary nocturnal enuresis, and nephrogenic diabetes insipidus caused by new mutations in the aquaporin-2 gene (AQP2). The mutant AQP2 proteins were inactive, suggesting that administration of desmopressin could not concentrate the urine in these patients. However, treatment with desmopressin resolved primary nocturnal enuresis completely. This observation questions the notion that desmopressin resolves primary nocturnal enuresis through pharmacological manipulation of renal concentrating ability only. Desmopressin might also act on extrarenal targets such as the central nervous system.

• Authors: Dominik Müller, Nannette Marr, Tobias Ankermann, Paul Eggert, Peter M T Deen
• Journal: Lancet (London, England) (Lancet) Vol. 359 Issue 9305 Pg. 495-7 (Feb 09 2002) ISSN: 0140-6736 [Print] England
• PMID: 11853799 (Publication Type: Letter, Research Support, Non-U.S. Gov't)

Chemical References

• Renal Agents
• Deamino Arginine Vasopressin

Topics

• Child
• Deamino Arginine Vasopressin (therapeutic use)
• Diabetes Insipidus, Nephrogenic (genetics)
• Enuresis (drug therapy, genetics)
• Humans
• Pedigree
• Renal Agents (therapeutic use)